

Re: Pathfinder Risk Management Platform

To whom it may concern,

We are delighted to announce that we have received a conditional approval from the MHRA for the Pathfinder risk management platform. This means that we will begin the registration of Prescribers and pharmacists that belong to an Inpatient, Outpatient or Homecare pharmacy on 17-Oct-2022.

With this early access to registration, you will have the user guide, training video`s and Healthcare Professional Information guide available for your disposal. Through our collaboration with the NHS and the BGMA, we will communicate the live date which will be a time within the month of October. Registration and training materials are available here: <http://pathfinderrmp.co.uk/>

The Pathfinder RMP will be providing access to Healthcare Professionals in a 2-phase approach.

We will be granting access to Prescribers and Inpatient Pharmacists on our initial launch date and access to Outpatient and Homecare Pharmacist within a short succession on a later launch date.

This means that for the first stage Prescribers will send Prescription Authorisation Forms to their inpatient pharmacy, who will be the key dispensing point for the patient receiving lenalidomide. With the second stage launch homecare and out-patient pharmacies can be used as dispensing points. The second phase launch is scheduled for early November.

If you have any questions or would like personalised training please contact support@pharmacaregroup.co.uk.

We appreciate the collaboration and feedback from Pharmacists, Prescribers and Patient Advocates to get Pathfinder to where it is today,

Kind Regards,

The Pathfinder RMP Team